GSK, German Merck's $4.2B bintrafusp alfa drug flops again, but companies squint to see glimmers of hope GBT adds 2 Sanofi sickle cell meds to its pipeline in deal worth up to $353M Lilly's Skyrizi rival hits goal in ulcerative colitis phase 3, as it ups the ante against AbbVie In Partnership: Meeting the challenge to deliver COVID-19 relief around the world GSK kick-starts phase 3 Medicago-partnered COVID vaccine test Alnylam clinical development vet becomes Beam Therapeutics CMO Solid Bio safely doses DMD gene therapy after exiting FDA hold Roche to pick up GenMark Diagnostics in $1.8B infectious disease testing deal Clinical trial firms tap social media 'influencers' for virtual trial recruitment drive Featured Story | By Ben Adams Two months after GlaxoSmithKline and Merck KGaA’s oncology asset bintrafusp alfa failed to beat out King Keytruda in certain lung cancers, it has followed up with another disappointment. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus As Global Blood Therapeutics works to bring its sickle cell disease drug, Oxbryta, to younger patients, the company is bolstering its pipeline with a pair of early-stage programs from Sanofi. The French pharma will receive up to $353 million in an undisclosed upfront fee and potential development, regulatory and commercial milestone payments down the line. read more By Nick Paul Taylor A phase 3 clinical trial of mirikizumab in ulcerative colitis has met its primary endpoint, boosting Eli Lilly’s hopes of establishing the anti-IL-23p19 antibody in gastrointestinal disorders. read more In Partnership With: AmerisourceBergen Each challenge COVID-19 has presented in the past year has seemed insurmountable yet at every step those obstacles have been overcome, particularly in the pharmaceutical industry tasked with developing vaccines and therapies to combat this crisis. read more By Ben Adams GlaxoSmithKline and Sanofi tripped up in a recent COVID-19 vaccine test, but the U.K. Big Pharma is hoping for better luck with its second partner Medicago. read more By Amirah Al Idrus As Beam Therapeutics sets its sights on the clinic, it has signed on a new chief medical officer. Amy Simon, M.D., arrives from Alnylam, where she held various roles over a decade, culminating in vice president of clinical development. read more By Nick Paul Taylor Solid Biosciences has given its Duchenne muscular dystrophy gene therapy without causing the sort of adverse events that forced it to shutter the study in 2019. The experience provides early evidence that the manufacturing changes and clinical mitigation strategy could rescue the program. read more By Conor Hale Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously. read more By Ben Adams As the hype around so-called siteless trials continues unabated, two trial tech firms are joining forces to tap social media influencers to help push more patients into studies. read more Resources Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored By: OCT Clinical Find out why more than 400 clinical trials annually are initiated in Russia by US and EU pharma in the free annual report by OCT Clinical. Sponsored by: Uncountable Interested in moving from hand-written lab notebooks or spreadsheets to a modern research platform? Read this guide on Lab Information Management Systems (LIMS) to learn how modern companies are using software to innovate faster. Sponsored By: Almac Clinical Technologies This industry report reveals qualitative and quantitative candid insight from clinical development insiders and their views on current clinical trial challenges faced amidst uncertainty. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: AmerisourceBergen Corporation Unlock product potential by making the most of your commercialization investments. Sponsored By: Culture Biosciences Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly. Sponsored By: Acorn AI Unlock competitive advantage with AI and advanced analytics. Sponsored By: EVERSANA Mature brands lost billions in revenue and value during COVID, but with the right strategy, pharma can rebound and reignite revenue. Learn How. Sponsored By: BC Platforms Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. Sponsored By: Thermo Fisher Scientific Involved in vaccine development? Check out this timely infographic detailing the history of vaccines, key development milestones, and what challenges remain. Sponsored By: Blue Matter, strategic consultants in the life sciences A look ahead at how cell-based therapies in oncology will advance during 2021-22: research, regulatory, and commercial milestones. Sponsored by: Baxter BioPharma Solutions While service directories are filled with CMOs claiming vaccine fill-finish experience, the logistical challenges resulting from seasonal product are unique and it is important that outsourcing partners can ensure quality and on-time delivery. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Learn the science driving biopharma. Specific for the non-scientist. March 18-19, 2021 | 12 p.m. EST / 9 a.m. PST Global Clinical Quality April 7-8, 2021 | Virtual Event Learn what it takes to get a drug developed and approved April 13-14, 2021 | 12 p.m. EST / 9 a.m. PST
Learn the science driving biopharma. Specific for the non-scientist. April 20-21, 2021 | 12 p.m. EST / 9:00 a.m. PST Pharma PR & Communications Virtual Summit April 20–22, 2021 | Virtual Event 3rd Neuroimmunology Drug Development Summit 2021 April 27-29, 2021 Vaccines, cell and gene therapy, therapeutic antibodies and RNA drugs May 20-21, 2021 | 12 p.m. EST / 9 a.m. PST Vaccines, cell and gene therapy, antibodies, and RNA-based drugs June 10-11, 2021 | 9 a.m. EST / 6 a.m. PST Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. | 